These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 37221048)

  • 1. Neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene or
    Bhardwaj N; Das G; Srinivasan R
    J Clin Pathol; 2023 Aug; 76(8):518-523. PubMed ID: 37221048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAX to MYCN intracellular ratio drives the aggressive phenotype and clinical outcome of high risk neuroblastoma.
    Ferrucci F; Ciaccio R; Monticelli S; Pigini P; di Giacomo S; Purgato S; Erriquez D; Bernardoni R; Norris M; Haber M; Milazzo G; Perini G
    Biochim Biophys Acta Gene Regul Mech; 2018 Mar; 1861(3):235-245. PubMed ID: 29408445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and DNA-binding activity of MYCN/Max and Mnt/Max during induced differentiation of human neuroblastoma cells.
    Smith AG; Popov N; Imreh M; Axelson H; Henriksson M
    J Cell Biochem; 2004 Aug; 92(6):1282-95. PubMed ID: 15258910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the MYCN protein with small molecule c-MYC inhibitors.
    Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
    PLoS One; 2014; 9(5):e97285. PubMed ID: 24859015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MYCN oncoprotein as a drug development target.
    Lu X; Pearson A; Lunec J
    Cancer Lett; 2003 Jul; 197(1-2):125-30. PubMed ID: 12880971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4.
    Xue C; Yu DM; Gherardi S; Koach J; Milazzo G; Gamble L; Liu B; Valli E; Russell AJ; London WB; Liu T; Cheung BB; Marshall GM; Perini G; Haber M; Norris MD
    Oncotarget; 2016 Aug; 7(34):54937-54951. PubMed ID: 27448979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification.
    Valentijn LJ; Koster J; Haneveld F; Aissa RA; van Sluis P; Broekmans ME; Molenaar JJ; van Nes J; Versteeg R
    Proc Natl Acad Sci U S A; 2012 Nov; 109(47):19190-5. PubMed ID: 23091029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
    Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
    Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
    Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
    Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression.
    Hagemann S; Misiak D; Bell JL; Fuchs T; Lederer MI; Bley N; Hämmerle M; Ghazy E; Sippl W; Schulte JH; Hüttelmaier S
    Mol Cancer; 2023 May; 22(1):88. PubMed ID: 37246217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumorigenic proteins upregulated in the MYCN-amplified IMR-32 human neuroblastoma cells promote proliferation and migration.
    Zaatiti H; Abdallah J; Nasr Z; Khazen G; Sandler A; Abou-Antoun TJ
    Int J Oncol; 2018 Mar; 52(3):787-803. PubMed ID: 29328367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PLAGL2/MYCN/miR-506-3p interplay regulates neuroblastoma cell fate and associates with neuroblastoma progression.
    Zhao Z; Shelton SD; Oviedo A; Baker AL; Bryant CP; Omidvarnia S; Du L
    J Exp Clin Cancer Res; 2020 Feb; 39(1):41. PubMed ID: 32087738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma.
    Rajbhandari P; Lopez G; Capdevila C; Salvatori B; Yu J; Rodriguez-Barrueco R; Martinez D; Yarmarkovich M; Weichert-Leahey N; Abraham BJ; Alvarez MJ; Iyer A; Harenza JL; Oldridge D; De Preter K; Koster J; Asgharzadeh S; Seeger RC; Wei JS; Khan J; Vandesompele J; Mestdagh P; Versteeg R; Look AT; Young RA; Iavarone A; Lasorella A; Silva JM; Maris JM; Califano A
    Cancer Discov; 2018 May; 8(5):582-599. PubMed ID: 29510988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The mycN/max protein complex in neuroblastoma. Short review.
    Wenzel A; Schwab M
    Eur J Cancer; 1995; 31A(4):516-9. PubMed ID: 7576956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.
    Boboila S; Lopez G; Yu J; Banerjee D; Kadenhe-Chiweshe A; Connolly EP; Kandel JJ; Rajbhandari P; Silva JM; Califano A; Yamashiro DJ
    Oncogene; 2018 Oct; 37(40):5451-5465. PubMed ID: 29880876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.